An open-label, single-group, multicenter Phase II study testing DCVAC/OvCa in combination with standard of care chemotherapy for patients with ovarian cancer after first relapse

Trial Profile

An open-label, single-group, multicenter Phase II study testing DCVAC/OvCa in combination with standard of care chemotherapy for patients with ovarian cancer after first relapse

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs DCVAC OvCa (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors SOTIO
  • Most Recent Events

    • 01 Dec 2017 New trial record
    • 28 Nov 2017 This trial is conducted in collaboration with CEEGOG (Central and Eastern European Gynecological Oncology Group), as reported in a SOTIO media release.
    • 28 Nov 2017 According to a SOTIO media release, first patient has been enrolled t the General University Hospital in Prague at the department of Professor David Cibula in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top